Page images
PDF
EPUB
[ocr errors]

minsan of the marketing of five

P** 13 1ste trarket, resulting in

iRDerrice programs for action-

HI FI TR TT-P Stereo Medical Association Pago

TOT I bet ires.

525

1 27151 01 Lerean physician. Part II.

25-n icine weş made for the Ameri-

*** r 'n s Issociates. Chapter VII.

3-4 zyrt meegtaree.

528

231 Bei activities, 1950–58. 530

keema leiri Association, July 24,

***Priceoria'ions.

531

Kerttee chart).

128
Dimary to March, 1953-61 (sub-

131
.************

VL selected drug companies,
Hermie :-

132

da December 31, 1960, with

534

535

XESTES *** ESS

ad from J.A.M.A., August

536

- JAM.A., September 10, 1960.. 538

30.ML.Fort 25. ignil.

540

DRL in Office Practice, Dr.

PST 13. Fi..JIVI, October 1, 1960

542

2:11. Virti..

549

I TILL. Van II. Lol..

551

$320.823cc oprobamate, from New and Nonofficial

553

2

SUVLAN let)

554

23 TPBJAVLJ:r 1960. and “Status and Prospect of

sicher" Enost to the Council on Drugs, Dr. Walter

VOJUVrlonil.

556

23 “Te Teezerske Urgent Veed for Reform," New England

J*** Wire Jur 7. 1900..

566

-Te Firmaer azd Chemistry- Membership, Activities,

Vadorra, Attainments," Dr. Austin Smith, J.A.M.A.,

Fibar 12.

569

8 “United States Ford Drug Administration and the Pharmaceutical

Irir;" hr Dr. Joseph Garland, British Medical Journal, May

Toril

576

2. Alinsulations and actions, presented by State medical associations.. 579

it Cote for levertising, the Phisicians' Council, August 1957.

31. Further emples of promotional "education," submitted by Dr.

(hark's day

603

32 derrusemenis and accompanying material submitted by Dr. Charles

Man

617

31 IU Social Processes in Physicians' Adoption of a New Drug,

Jamie's (oleman, et al., Journal of Chronic Diseases, January

1939

648

31:) "Dimensions of Being Modern' in Medical Practice," Herbert

667

Mendel, et al., Journal of Chronic Diseases, January 1939.
33. "The Transcrutical Industry,” John G. Searle, et al., of the Proies-
sional Relations Committee, Pharmaceutical Manufacturers Asso-

OSS
rintion

34. The tom du Lac study: An intensive study of the marketing nf five

1 ethical pharmaceutical products in a single market, resulting in

Nemo theory of scientific marketing and service programs for activa-

lemarketing study made for the American Vedical Associs ion

697

bor Hen Gatlin all Associates (full text).

20 liter from Will, Reynolds, General Mills, Inc., Minneapolis, Nina,

to Rowentative Clark MacGregor, July 10, 1961, wih coveries

loftor hom Hepresentative MacGregor to Senator Dirksea, Ig 14,

807

[ocr errors]
[ocr errors]

37. Letter from Noble J. Swearingen, director, Washington Office, Ameri-

can Public Health Association, July 14, 1961, enclosing statement Page

810

and resolutions of APHA..

38. "Hazards of Modern Diagnosis and Therapy—The Price We Pay,"

815

Dr. David P. Barr, J.A.M.A., December 10, 1955..

39. "The Testing of New Drugs and Other Therapeutic Agents," Dr.

820

Isaac Starr, J.A.M.A., July 8, 1961...

40. "Do Trade Name Drugs Cost Extra?” Good Housekeeping magazine,

829

July 1961..

41. "Generic Prescribing? It Could Be Dangerous," Medical Economics,

831

July 3, 1961.

42. "Efects of S. 1552 on the Public's Health," Eli Lilly & Co., June 30,

832

1961....

43. "The Drug Explosion,” Dr. Water Modell

, Clinical Pharmacology and

Therapeutics, January-February 1961.

849

4. "Too Many Drugs,” Time magazine, May 26, 1961, relating to article

by Dr. Walter Modell in Chemical Pharmacology and Therapeutics. 856

45. Letter by Dr. Austin Smith, Time magazine, June 16, 1961, com-

menting on previous article

856

46. Statement by Dr. Allan M. Butler, September 2, 1961, on false state-

ments by drug industry.

857

47. Codes and procedures of Physicians' Council, August 1947

861

48. Norlutin ad, J.A.M.A., April 30, 1960.

877

4. Norlutin ad, J.A.M.A., April 23, 1960.

878

50. Norlutin ad, J.A.M.A., October 22, 1960.

879

51. Norlutin package insert.--

881

52. Report on Norlutin, Council on Drugs of A.M.A., volume 169, No.11. 895

53. "The Clinical Value of Drugs: Sources of Evidence," Dr. Vindel C.

Sheps, American Journal of Public Health, May 1961...

54. Notice of proposal to amend labeling requirements, enforcement rega

lations drugs and devices, new drugs; Food and Drug Administra

tion; Federal Register, July 22, 1960.

35. "Chemical structure of Tetracyc.ine, Chiortetraeyeite, and OITAI-

eyeline," _Patent Ownership and Licensing in Antibiotics Industry.

Federal Trade Commission.

OTHER MATERIAL

Opening statement by Senator Kefauver.

Opening statement by Senator Dirksen..

Comparison of S. 1552 and present law which it woli smesi 5.miru

print)

" Amendment of Antitrust Laws with respect to launch

tribution of Drugs," statement by Seta:ct Kesz: 2

1961.

"Kelly

, PMA Counsel, Analyzes Kesuvez-Cent Biz Izde

[ocr errors]

News, May 1, 1961.

Additional ads:

Weight depressants:

Tepanil

, J.A.M.A., February 14. 1961.

Preludin, J.A.M.A., April 1. 196L.
Preludin, J.A.M.A., December 2. 1970
Didrex, J.A.M.A., February 3. 1960-
Desbital, J.A.M.A., Marea B. 191
Bamades, JAMA, March 11, 131

Appetrol, J.A.M.A, March 25, 161

Synthetic penicillins:

Alpen, J.A.M.A., April 30, 1960

Chemipen, J.AMAS

Syncillin, J.A.M.A., January 14, LL.

Muzipen, J.AMA, April 1, 1961.
Biographical material:

Dr. Charles D. May

Dr. Louis 8. Goodins
Bling Drugs by 'Eclocating Persicians," Dr. Chara 3 Vlag vina

Wedical Education, Jases1901.

[graphic]

-

531

128

131

132

8. The Fond du Lac study: An intensive study of the marketing of five

new ethical pharmaceutical products in a single market, resulting in

some theory of scientific marketing and service programs for action-

a basic marketing study made for the American Medical Association

by Ben Gaffin & Associates. Chapter 1. Objectives.

9. A study of medical advertising and the American physician. Part II.

The physicians' viewpoint-an opinion survey made for the Ameri-

can Medical Association by Ben Gaffin & Associates. Chapter VII.

Attitudes of physicians toward council acceptance.

10. Expenses of AMA councils, bureaus, and related activities, 1950–58..

11. Letter from Dr. Blasingame, American Medical Association, July 24,

1961, relating to Council on Drugs appropriations-

12. AMA income by source, 1949-60 (subcommittee chart).
13. Pages of advertising in J.A.M.A., January to March, 1953–61 (sub-

committee chart)

14. Advertising expenditures in J.A.M.A., 22 selected drug companies,

1955, 1958, 1960 (subcommittee chart).

15. AMA statement of income, year ended December 31, 1960, with

comparative figures for 1959

16. AMA income from addressing companies..

17. “Why we sometimes ask questions * * *” ad from J.A.M.A., August

6, 1960

18. Clarity is our aim * * *" ad from J.A.M.A., September 10, 1960..

19. DBI ad, J.A.M.A., February 25, 1961.

20. “Clinical Evaluation of Phenformin (DBI) in Office Practice," Dr.

Paul L. Barclay, Erie, Pa., J.A.M.A., October 1, 1960.-

21. Equanil ad, J.A.M.A., March 4, 1961.

22. Miltown ad, J.A.M.A., March 11, 1961.

23. Statement on side effects of meprobamate, from New and Nonofficial

Drugs, 1961.

24. Soma ad, J.A.M.A., April 30, 1960

25. Tenuate ad, J.A.M.A., July 9, 1960, and “Status and Prospect of

Drugs for Overeating,'' Report to the Council on Drugs, Dr. Walter

Modell, J.A.M.A., July 9, 1960.-

26. "Drug Terminology and the Urgent Need for Reform," New England

Journal of Medicine, July 7, 1960.

27. “The Council on Pharmacy and Chemistry- Membership, Activities,

Method of Operation, Attainments,” Dr. Austin Smith, J.A.M.A.,

February 12, 1955.

28. “United States Food and Drug Administration and the Pharmaceutical

Industry," by Dr. Joseph Garland, British Medical Journal, May

20, 1961

29. AMA resolutions and actions, presented by State medical associations..

30. Code for Advertising, the Physicians' Council, August 1957..

31. Further examples of promotional "education," submitted by Dr.

Charles May

32. Advertisements and accompanying material submitted by Dr. Charles

May

32A. (1) "Social Processes in Physicians' Adoption of a New Drug,"

James Coleman, et al., Journal of Chronic Diseases, January

1959..

32A. (2) "Dimensions of Being 'Modern' in Medical Practice," Herbert

Menzel, et al., Journal of Chronic Diseases, January 1959-

33. "The Pharmaceutical Industry," John G. Searle, et al., of the Profes-

sional Relations Committee, Pharmaceutical Manufacturers Asso-

ciation.

34.* The Fond du Lac study: An intensive study of the marketing of five

new ethical pharmaceutical products in a single market, resulting in

some theory of scientific marketing and service programs for action--

A basic marketing study made for the American Medical Association

by Ben Gaffin & Associates (full text).

36. Letter from W. B. Reynolds, General Mills, Inc., Minneapolis, Minn.,

to Representative Clark MacGregor, July 10, 1961, with covering
letter from Representative MacGregor to Senator Dirksen, July 14,

1961.----
*Exbibit 35 was not provided.

648

807

832

37. Letter from Noble J. Swearingen, director, Washington Office, Ameri-

can Public Health Association, July 14, 1961, enclosing statement

and resolutions of APHA.-

38. "Hazards of Modern Diagnosis and Therapy-The Price We Pay,"

Dr. David P. Barr, J.A.M.A., December 10, 1955.-

39. “The Testing of New Drugs and Other Therapeutic Agents,” Dr.

Isaac Starr, J.A.M.A., July 8, 1961.-

40. "Do Trade Name Drugs Cost Extra?” Good Housekeeping magazine,

July 1961...

41. "Generic Prescribing? It Could Be Dangerous," Medical Economics,

July 3, 1961..

42. “Effects of S. 1552 on the Public's Health," Eli Lilly & Co., June 30,

1961..

43. “The Drug Explosion," Dr. Walter Modell, Clinical Pharmacology and

Therapeutics, January-February 1961..

44. "Too Many Drugs," Time magazine, May 26, 1961, relating to article

by Dr. Walter Modell in Chemical Pharmacology and Therapeutics -

45. Letter by Dr. Austin Smith, Time magazine, June 16, 1961, com-

menting on previous article

46. Statement by Dr. Allan M. Butler, September 2, 1961, on false state-

ments by drug industry--

47. Codes and procedures of Physicians' Council, August 1947-

48. Norlutin ad, J.A.M.A., April 30, 1960-

49. Norlutin ad, J.A.M.A., April 23, 1960-

50. Norlutin ad, J.A.M.A., October 22, 1960..

51. Norlutin package insert.-

52. Report on Norlutin, Council on Drugs of A.M.A., volume 169, No. 11.

53. “The Clinical Value of Drugs: Sources of Evidence,” Dr. Mindel C.

Sheps, American Journal of Public Health, May 1961.

54. Notice of proposal to amend labeling requirements, enforcement regu-

lations drugs and devices, new drugs; Food and Drug Administra-

tion; Federal Register, July 22, 1960. -

55. “Chemical structure of Tetracycline, Chlortetracycline, and Oxytetra-

cycline,” Patent Ownership and Licensing in Antibiotics Industry,

Federal Trade Commission....

26

531

128

131

132

553

551

8. The Fond du Lac study: An intensive study of the marketing of five

new ethical pharmaceutical products in a single market, resulting in

some theory of scientific marketing and service programs for action-

a basic marketing study made for the American Medical Association

by Ben Gaffin & Associates. Chapter 1. Objectives.

9. A study of medical advertising and the American physician. Part II.

The physicians' viewpoint-an opinion survey made for the Ameri-

can Medical Association by Ben Gaffin & Associates. Chapter VII.

Attitudes of physicians toward council acceptance.

10. Expenses of AMA councils, bureaus, and related activities, 1950-58.

11. Letter from Dr. Blasingame, American Medical Association, July 24,

1961, relating to Council on Drugs appropriations.

12. AMA income by source, 1949–60 (subcommittee chart)
13. Pages of advertising in J.A.M.A., January to March, 1953–61 (sub-

committee chart)

14. Advertising expenditures in J.A.M.A., 22 selected drug companies,

1955, 1958, 1960 (subcommittee chart).

15. AMA statement of income, year ended December 31, 1960, with

comparative figures for 1959-

16. AMA income from addressing companies

17. “Why we sometimes ask questions * * *” ad from J.A.M.A., August

6, 1960.

18. "Claritv is our aim * * *' ad from J.A.M.A., September 10, 1960..

19. DBI ad, J.A.M.A., February 25, 1961.

20. “Clinical Evaluation of Phenformin (DBI) in Office Practice, Dr.

Paul L. Barclay, Erie, Pa., J.A.M.A., October 1, 1960.

21. Equanil ad, J.A.M.A., March 4, 1961.

22. Miltown ad, J.A.M.A., March 11, 1961.

23. Statement on side effects of meprobamate, from New and Nonofficial

Drugs, 1961..

24. Soma ad, J.A.M.A., April 30, 1960-
25. Tenuate ad, J.A.M.A., July 9, 1960, and “Status and Prospect of

Drugs for Overeating,” Report to the Council on Drugs, Dr. Walter

Modell, J.A.M.A., July 9, 1960.-

26. “Drug Terminology and the Urgent Need for Reform," New England

Journal of Medicine, July 7, 1960.

27. “The Council on Pharmacy and Chemistry- Membersbip, Activities,

Method of Operation, Attainments," Dr. Austin Smith, J.A.M.A.,

February 12, 1955...

28. “United States Food and Drug Administration and the Pharmaceutical

Industry,” by Dr. Joseph Garland, British Medical Journal, May

20, 1961,

29. AMÁ resolutions and actions, presented by State medical associations..

30. Code for Advertising, the Physicians' Council, August 1957.

31. Further examples of promotional "education," submitted by Dr.

Charles May..

32. Advertisements and accompanying material submitted by Dr. Charles

May.

32A. (1) "Social Processes in Physicians' Adoption of a New Drug,"

James Coleman, et al., Journal of Chronic Diseases, January

1959..

32A. (2) "Dimensions of Being 'Modern' in Medical Practice," Herbert

Menzel, et al., Journal of Chronic Diseases, January 1959....

33. “The Pharmaceutical Industry,” John G. Searle, et al., of the Profes-

sional Relations Committee, Pharmaceutical Manufacturers Asso-

ciation.

34.* The Fond du Lac study: An intensive study of the marketing of five

new ethical pharmaceutical products in a single market, resulting in

some theory of scientific marketing and service programs for action-

A basic marketing study made for the American Medical Association

by Ben Gaslin & Associates (full text).

36. Letter from W. B. Reynolds, General Mills, Inc., Minneapolis, Minn.,

to Representative Clark MacGregor, July 10, 1961, with covering
letter from Representative MacGregor to Senator Dirksen, July 14,

1961..---
*Exhibit 35 was not provided.

648

807

« PreviousContinue »